Sutent

(Sunitinib Malate)

Phase 3

CCp Cv

Sutent is one of 40 small molecule programs targeting Advanced Lymphoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Advanced LymphomaActive, not recruiting

Stage IIIB Lung Non-Small Cell Cancer AJCC V7Completed

Clear Cell Renal Cell CarcinomaCompleted

Advanced LymphomaPhase 2

Active, not recruiting

Stage IIIB Lung Non-Small Cell Cancer AJCC V7Phase 3

Completed

Clear Cell Renal Cell CarcinomaPhase 3

Completed

Competition

Competitive Landscape

31 competitors in Advanced Lymphoma

#DrugCompanyPhaseTrials

Ibrance

Pfizer

Phase 2

2 2

Tafinlar

Novartis

Phase 2

1 3

Balversa

Johnson & Johnson

Phase 2

1 4

Alinamin

Roche

Phase 2

1 5

Vitrakvi

Bayer

Phase 2

1 6

Opdivo

Bristol-Myers Squibb

Phase 2

1 7

Tagrisso

AstraZeneca

Phase 2

1 8

Perjeta

Roche

Phase 2

1 9

Opdualag

Bristol-Myers Squibb

Phase 2

1 10

Mekinist

Novartis

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Advanced Lymphoma

NCT02465060

Clinical

Trials by Indication[1]

Advanced Lymphoma1 trial

Molecular Analysis for Therapy Choice (MATCH)

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT02465060·6,452 enrolled

Stage IIIB Lung Non-Small Cell Cancer AJCC v71 trial

Randomized, Phase III, Double-Blind Placebo-Controlled Trial of Sunitinib (NSC #736511) as Maintenance Therapy in Non-progressing Patients Following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced, Stage IIIB / IV Non-small Cell Lung Cancer

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00693992·210 enrolled

Clear Cell Renal Cell Carcinoma1 trial

ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00326898·1,943 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 26, 2006

SUTENT

NDA NDA021938

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Sunitinib Malate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sunitinib Malate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sunitinib Malate. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA021938). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Cp Cv company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: CCp Cv

Sutent

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Advanced Lymphoma1 trial

Stage IIIB Lung Non-Small Cell Cancer AJCC v71 trial

Clear Cell Renal Cell Carcinoma1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News